Clinical trials
Completed Disease Progression trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
161 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 1 |
| 2002 | 2 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 3 |
| 2007 | 6 |
| 2008 | 5 |
| 2009 | 5 |
| 2010 | 7 |
| 2011 | 10 |
| 2012 | 15 |
| 2013 | 8 |
| 2014 | 7 |
| 2015 | 11 |
| 2016 | 10 |
| 2017 | 8 |
| 2018 | 6 |
| 2019 | 8 |
| 2020 | 10 |
| 2021 | 4 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 161 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 12 |
| National Cancer Institute (NCI) | 5 |
| Massachusetts General Hospital | 4 |
| University of Zurich | 4 |
| AstraZeneca | 3 |
| Monteris Medical | 3 |
| AGC Biologics S.p.A. | 2 |
| Ain Shams University | 2 |
| Asan Medical Center | 2 |
| Bayer | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Disease Progression | 161 |
| Recurrence | 19 |
| HIV Infections | 18 |
| Brain Neoplasms | 9 |
| Breast Neoplasms | 9 |
| Urinary Bladder Neoplasms | 8 |
| Neoplasm Metastasis | 7 |
| Acquired Immunodeficiency Syndrome | 6 |
| COVID-19 | 6 |
| Multiple Myeloma | 6 |
Trials
Showing 76 to 100 of 161. Each trial links to its page on Pharma Observatory.
61 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.